EMV Capital Acquires Destiny Pharma's XF Drug Platform in Up to £2.475m Deal

EMV Capital picks up Destiny Pharma’s XF-73 platform out of liquidation

EMV Capital plc has secured an asset purchase agreement to acquire key assets from Destiny Pharma Limited’s XF drug platform via its wholly owned subsidiary, Moirai Acquisitions Limited (Bidco). The headline number is up to £2,475,000, but the immediate cash outlay is just £475,000 (plus VAT), with the balance tied to success milestones. This is classic EMV Capital: capital-light on day one, with upside if the science progresses.

Destiny Pharma, formerly AIM-quoted, had advanced its lead compound XF-73 to Phase 2b in a nasal gel aimed at preventing post-surgical infections, including MRSA. The company later entered administration and then liquidation, creating an opportunity for EMV Capital to step in and structure a deal around future value.

Deal structure: up to £2.475 million, mostly success-based

Bidco has acquired Destiny’s trading name, website and certain assets tied to XF-73 and associated compounds, including intellectual property, stock and contracts.

• Initial consideration: £475,000 cash (plus VAT), paid on completion.
• Deferred consideration: up to £2,000,000 (plus VAT) split as:
  • £600,000 on launching a US FDA Phase 3 clinical trial for XF-73.
  • £900,000 on receiving US regulatory approval to market the XF-73 product.
  • Up to £500,000 if Bidco receives a one-off milestone fee under a regional development and commercialisation agreement with the investment arm of a large pharma headquartered in Hong Kong.

In plain English: EMV Capital pays a modest amount now and only pays the rest if the asset progresses through major value inflection points. That reduces downside if development stalls, and aligns cash outflows with success.

Funding: loan with 100% warrant coverage and an EIS-targeted equity round

The £475,000 initial payment has been funded by third-party lenders syndicated by EMV Capital Partners Limited, the Group’s venture capital and corporate finance arm. The loan runs for three years and comes with 100 per cent warrant coverage. Warrants give lenders the right to buy shares at a set price, which can boost their return but may dilute other shareholders if exercised.

Bidco plans further fundraising before any Phase 3 start or US approval to cover those milestone-triggered deferred payments and broader development costs. The portion of deferred consideration linked to the Hong Kong regional milestone would be paid out of the milestone receipt itself.

On top, EMV Capital Partners has led an equity round to raise up to £725,000 for Bidco working capital. This is expected to complete in September 2025 after post-acquisition structuring to allow Enterprise Investment Scheme (EIS) participation, which can offer UK investors tax reliefs.

What this does for EMV Capital’s assets under management

Assuming the full £725,000 equity fundraising completes, EMV Capital expects c.£1.86 million of value in Bidco to be added to the Group’s assets under management (AUM):

• EMV Capital’s direct equity in Bidco: 43.8% of issued share capital (30% fully diluted if all warrants are exercised), fair value c.£560,000. Notably, this is “entirely a gain” to EMVC minus an initial cash investment of just £100.
• Third-party AUM with Bidco: 56.2% (70% fully diluted if all warrants are exercised), fair value c.£1.3 million.

AUM growth matters for a venture group like EMV Capital. It supports management fees, strengthens the investment platform and can compound value as portfolio assets scale. Worth stressing: AUM is not cash, and fair values can move with progress or setbacks.

XF-73: why this antimicrobial asset could be interesting

Destiny Pharma’s XF platform targets a major problem: antimicrobial resistance (AMR). XF-73 had completed Phase 2b as a nasal gel aimed at preventing post-surgical infections, particularly those caused by S. aureus (including MRSA). The combination of clinical progress and a real-world need makes it a credible late-stage candidate if funding and execution line up.

Key potential benefits of the XF platform highlighted in the RNS

• Ultra-rapid bacteria kill.
• Activity against bacteria in any growth phase.
• Ability to kill bacteria within staphylococcal biofilms.
• Active against all Gram positive bacteria tested to date and selected Gram negative bacteria.
• No bacterial (MRSA) resistance seen to emerge.

Phase 3 is the late-stage pivotal trial needed in the US before approval. The RNS does not disclose timelines for Phase 3 or regulatory submissions.

Key numbers from the announcement

Item	Amount / Detail
Total consideration	Up to £2,475,000 (plus VAT)
Initial consideration	£475,000 (plus VAT)
Deferred consideration	Up to £2,000,000 (plus VAT)
Deferred triggers	£600,000 (Phase 3 launch); £900,000 (US approval); up to £500,000 (regional milestone)
Loan terms	3-year term loan; 100% warrant coverage
Bidco equity raise (working capital)	Up to £725,000, targeted September 2025 completion (EIS eligible)
EMVC equity in Bidco	43.8% (30% fully diluted if all warrants exercised); fair value c.£560,000
Third-party AUM (Bidco)	56.2% (70% fully diluted); fair value c.£1.3 million
Total AUM uplift (assumed full raise)	c.£1.86 million
Destiny Pharma status	Administration (21 Aug 2024); Liquidation (1 Aug 2025)

My take: shrewd, capital-efficient move with the usual biotech risks

Positives first. EMV Capital has bought a late-stage antimicrobial asset for a modest upfront cost, with the bulk of the price payable only on success. That is sensible risk-sharing. The AUM uplift and the fair value of EMVC’s stake (c.£560,000) against a £100 initial cash investment show the firm’s venture-building model in action.

There are risks. Funding is still required to get to Phase 3 and beyond, and the loan includes warrant coverage that could dilute holdings if exercised. Clinical and regulatory uncertainty is inherent: the RNS does not disclose Phase 3 timing, trial design, or the size and terms of the regional development agreement in Hong Kong that underpins the potential milestone. Execution on fundraising – including the EIS round – is key.

Overall, for EMV Capital shareholders, this is a smartly structured option on a meaningful AMR opportunity. Success would be transformative for Bidco and value accretive for the Group, but progress updates and financing will determine how quickly that optionality turns into realised value.

What to watch next

• Completion of the up to £725,000 Bidco equity fundraising in September 2025 (EIS eligibility post-structuring).
• Any guidance on Phase 3 trial launch for XF-73 in the US – the £600,000 milestone trigger.
• Regulatory pathway updates towards US approval – tied to the £900,000 milestone.
• Details or receipts of the regional milestone from the Hong Kong-headquartered pharma investor – up to £500,000 of deferred consideration depends on this.
• Changes in EMV Capital’s AUM and any dilution effects from the loan’s 100% warrant coverage.

The announcement states it contained inside information at release but is now in the public domain. From here, the story is all about financing, trial initiation, and regulatory momentum. If EMV Capital can marshal those pieces, this could become one of its more compelling venture-building case studies.